Max Chat
Company Analysis Hologic
1. Summary
Advantages
- Current debt level 29.03% is below 100% and has decreased over 5 years from 46.29%.
- The company's current efficiency (ROE=15.56%) is higher than the sector average (ROE=14.17%)
Disadvantages
- Price (64.27 $) is higher than fair price (36.6 $)
- Dividends (0%) are below the sector average (0.527%).
- The stock's return over the last year (-20.91%) is lower than the sector average (-0.4713%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Hologic | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1% | 0% | 0.1% |
| 90 days | 10.8% | 3.4% | 24.2% |
| 1 year | -20.9% | -0.5% | 11.6% |
HOLX vs Sector: Hologic has significantly underperformed the "Healthcare" sector by -20.44% over the past year.
HOLX vs Market: Hologic has significantly underperformed the market by -32.48% over the past year.
Stable price: HOLX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: HOLX with weekly volatility of -0.4021% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (64.27 $) is higher than the fair price (36.6 $).
Price is higher than fair: The current price (64.27 $) is 43.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (24.44) is lower than that of the sector as a whole (64.31).
P/E vs Market: The company's P/E (24.44) is lower than that of the market as a whole (89.99).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.76) is lower than that of the sector as a whole (18.97).
P/BV vs Market: The company's P/BV (3.76) is lower than that of the market as a whole (9.37).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.79) is lower than that of the sector as a whole (32.77).
P/S vs Market: The company's P/S indicator (4.79) is lower than that of the market as a whole (10.11).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.27) is lower than that of the sector as a whole (274.86).
EV/Ebitda vs Market: The company's EV/Ebitda (15.27) is lower than that of the market as a whole (51.19).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -5.9% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-5.9%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (15.56%) is higher than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (15.56%) is higher than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (8.63%) is higher than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (8.63%) is higher than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (22.48%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (22.48%) is higher than that of the market as a whole (11.01%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 30.07.2024 | MACMILLAN STEPHEN P Chairman, President and CEO |
Sale | 81.7 | 3 597 990 | 44 039 |
| 30.07.2024 | MACMILLAN STEPHEN P Chairman, President and CEO |
Purchase | 26.21 | 1 154 260 | 44 039 |
| 17.07.2024 | MACMILLAN STEPHEN P Chairman, President and CEO |
Purchase | 26.21 | 96 243 | 3 672 |
| 17.07.2024 | Stamoulis Christiana Director |
Sale | 79.5 | 718 601 | 9 039 |
| 17.07.2024 | Stamoulis Christiana Director |
Purchase | 26.74 | 241 703 | 9 039 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
